10-Q quarterly report · filed Nov 9, 2026

TG THERAPEUTICS, INC. (TGTX) Q3 2026 10-Q Quarterly Report

Short answer

TG THERAPEUTICS, INC. (TGTX) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $260M (up 60.7% year over year) with net income of $55M.

Q3 2026 key financials · XBRL

Revenue
$260M
+60.7% YoY · +8.2% QoQ
Net income
$55M
−85.8% YoY · +612.8% QoQ
Operating margin
33.0%
EPS (diluted)
$0.35
−85.5% YoY · +600.0% QoQ

Source: XBRL data from the TG THERAPEUTICS, INC. (TGTX) Q3 2026 10-Q on SEC EDGAR. USD.

TG THERAPEUTICS, INC. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $259.9M, up $98.2M YoY from $161.7M
  • BRIUMVI U.S. product revenue $232.6M, up from $152.9M YoY, best-performing product line
  • Gross margin 84% versus BRIUMVI U.S. margin 87%; net income $55.5M versus $390.9M
  • Nine-month operating cash flow $66.6M versus $(44.4)M YoY; financing provided $291.2M from 2026 Term Loan
  • Cash, equivalents and investments $556.7M; liquidity expected to fund operations beyond twelve months
  • Near-term headwinds: rising clinical, manufacturing, commercialization and interest expenses; subcutaneous BRIUMVI data expected year-end 2026 or Q1 2027

Risk Factors

  • Newly added AI risk: evolving EU AI Act and related rules could increase compliance costs and liability
  • Regulatory risk: OBBBA coverage changes and CMS payment pilots could reduce reimbursement for multiple sclerosis medicines
  • Operational risk: reliance on Samsung Biologics and FUJIFILM limits BRIUMVI supply resilience
  • Competitive risk: faster or more effective rival therapies could reduce BRIUMVI adoption
  • Financial risk: $750 million 2026 Term Loan matures March 18, 2031, secured by substantially all assets

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other TG THERAPEUTICS, INC. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.